Trial record 11 of 469 for:
"tetrasomy 18p" OR "Chromosomal Disorder"
Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2012 by Applied Spectral Imaging Ltd..
Recruitment status was Recruiting
Information provided by (Responsible Party):
Applied Spectral Imaging Ltd.
First received: June 13, 2012
Last updated: July 10, 2012
Last verified: May 2012
The purpose of the study is the identification of chromosomal aberrations in non-small cell lung cancer (NSCLC) .
The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classifying ALK FISH stained lung samples.
Non-small Cell Lung Cancer (NSCLC)
||Observational Model: Cohort
Time Perspective: Retrospective
||Concordance Study for Detection of Chromosomal Aberrations Using FISH (ALK Test)in Non-small Cell Lung Cancer (NSCLC)
| Estimated Enrollment:
| Study Start Date:
The ALK Break Apart FISH test detects chromosomal aberrations via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue specimens. The FDA approved ALK kit is designed to detect rearrangements involving the ALK gene (2p23). Results from the ALK Kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for the pathologist in the identification of patients eligible for treatment with XALKORI® (crizotinib).
|Ages Eligible for Study:
||20 Years to 90 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients having non-small cell lung cancer (NSCLC)
- Well stained slides with bright FISH signals
- Very old slides that were already bleached
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01620853
|Scott & White Hospital,
|Temple,, Texas, United States |
|Contact: Shila Dobin, Ph.D 254-724-3704 SDOBIN@swmail.sw.org |
|Principal Investigator: Shila Dobin, Ph.D |
Applied Spectral Imaging Ltd.
No publications provided
||Applied Spectral Imaging Ltd.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 13, 2012
||July 10, 2012
||United States: Institutional Review Board
Keywords provided by Applied Spectral Imaging Ltd.:
Non-small cell lung cancer (NSCLC)
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 18, 2014
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Genetic Diseases, Inborn